Introduction: The FTO gene, located on chromosome 16q12.2, is considered one of the key genes associated with obesity risk. Additionally, there are many diets worldwide that are tailored to each person's genetic profile.
Methods: This study used Megagene pharmacogenomic software to analyze polymorphic data extracted from the NCBI database, which served as the source and reference for the study, to identify side effects with a genetic basis.
Results: The three most popular SNPs that play a role in the development of obesity are RS17782313, RS9939609, and RS1799883. Furthermore, the side effects that individuals experience after using drugs to treat obesity are influenced by their personal genetic profile.
Conclusion: Before using commercial drugs to treat diseases such as obesity, genetic tests should be conducted on patients to detect the possible presence of polymorphisms in key genes like FTO. This approach allows for the prescription of drugs with fewer side effects if one or more of these polymorphisms are present in the patient.